High-fidelity vaccines

搜索文档
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
Newsfilter· 2025-03-30 21:00
Patrick Ryan, Executive Director, Corporate Affairs Vaxcyte, Inc. 415-606-5135 media@vaxcyte.com About Vaxcyte Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. VAX-31, a 31-valent PCV candidate advancing to a Phase 3 adult clinical program and currently being evaluated in a Phase 2 infant c ...